5-(morpholine-4-carbonyl)thiophene-3-sulfonyl chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-(morpholine-4-carbonyl)thiophene-3-sulfonyl chloride
• 英文别名: 5-(Morpholine-4-carbonyl)thiophene-3-sulfonyl chloride
• 化学式: C₉H₁₀ClNO₄S₂
• 分子量: 295.768
• InChiKey: AVFDSOICLPOYBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  100
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-[(morpholin-4-yl)carbonyl]thiophene-2-sulfonyl chloride 在 硫酸 作用下， 生成 5-(morpholine-4-carbonyl)thiophene-3-sulfonyl chloride
  参考文献：
  名称：

  Cremlyn, Richard J.; Goulding, Kenneth H.; Swinbourne, Frederick J., Phosphorus and Sulfur and the Related Elements, 1981, vol. 10, p. 111 - 120

  摘要：

  DOI：

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS
  申请人：CARDIOXYL PHARMACEUTICALS

  公开号：US20150366977A1

  公开（公告）日：2015-12-24

  The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

  本公开提供了含有N-取代羟胺衍生物的亚硝酰基供体药物组合物。该组合物在治疗心血管疾病（如心力衰竭）方面具有高效性，具有适当的毒理学特性，并且对于静脉或口服给药具有足够的稳定性。
• Pharmaceutical compositions comprising nitroxyl donors
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：US10245249B2

  公开（公告）日：2019-04-02

  The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

  本公开提供了由 N-取代的羟胺衍生物组成的硝基捐献药物组合物。这些组合物在治疗心血管疾病（如心力衰竭）方面疗效显著，具有合适的毒理学特征，并且足够稳定，可用于静脉注射或口服给药。
• EP3427728A1
  申请人：——

  公开号：EP3427728A1

  公开（公告）日：2019-01-16
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES DONNEURS NITROXYLE
  申请人：CARDIOXYL PHARMACEUTICALS INC

  公开号：WO2014113700A1

  公开（公告）日：2014-07-24

  The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.